Figure 1
Figure 2
Experience of use of factor IX products
| PRODUCT | N | % | |
|---|---|---|---|
| Standard half-life | |||
| Nonacog alfa | Benefix [31] | 47 | 80% |
| Nonacog gamma | Rixubis [32] | 11 | 19% |
| Extended half-life | |||
| Albutrepenonacog alfa | Idelvion [9] | 22 | 37% |
| Eftrenonacog alfa | Alprolix [8] | 36 | 61% |
| Nonacog beta pegol | Refixia/Rebinyn [10] | 13 | 22% |
| Other | 17 | 29% | |